

Ipilimumab CA184-024

PRELIMINARY SCORE

CURATIVE



Long-term plateau in the survival curve

NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



There is a long term plateau in the survival curve, and OS advantage continues to be observed at 5 years has also been scored according to form 1.



Ipilimumab CA184-024

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: Advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (Basis of EMA and FDA approval of 1st-line ipilimumab monotherapy)

Experimental Arm: Ipilimumab + Dacarbazine

Control Arm: Dacarbazine + placebo



